Share Your Content with Us
on for readers like you. LEARN MORE
Analysis paralysis? Build a better commercialization plan with these launch considerations

Request Your Free Article Now:

"Analysis paralysis? Build a better commercialization plan with these launch considerations"

The factors you should consider as you navigate commercialization

As small to midsize biopharma organizations turn the preclinical corner with their assets, things start to get real—real fast. A rapid-fire queue of considerations can suddenly land in your lap, many of them topics you haven't thought much about before, from market access and brand strategy to pricing, manufacturing, and patient services. Often, companies suffer analysis paralysis along the way, which poses many risks:

  • A delay in go-to-market planning, a competitor may beat you to it 
  • The market might be unprepared to receive your product
  • A hasty decision could jeopardize regulatory approval or revenue

Managing the tidal wave of pre-launch considerations is hard to do alone—regardless of whether you are launching a product to address an unmet need, or adding another option to an existing, competitive category. That’s why working with a partner to help navigate the complexities and developing a thoughtful commercialization launch plan can help you assess how much your infrastructure can support—and where assistance is warranted.

Offered Free by: Cencora
See All Resources from: Cencora

Recommended for Professionals Like You: